Sharemaestro company-news research for Biogen Inc (BIIB), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

BIIB news sentiment

Biogen Inc

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
30-day score52Neutral is 50
Early balanced news score 27/100 evidence confidence 100% direct company focus 13 current stories across 12 publishers
Latest weekly closeUSD 207.94week of 7 Aug 2026
Main news subjectEarnings75/100 share of current news
News data statusHealthy3 duplicate stories removed

Current company news

Early balanced news score

13 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone57/100 Published 30-day score52/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation finance.yahoo.com · 13 Aug 2026 13:52

What supports the score

Direct evidence

13 current stories are mapped specifically to BIIB.

Source breadth

The score uses 12 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.243.

Confidence

Confidence is 27/100, below the threshold for a firm score.

52/100
News scoreEarly balanced news score
27/100
Confidencethin evidence
100%/100
Company news13 company stories
89/100
Story agreement11/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
17 Jul: 1 stories22 Jul: 1 stories25 Jul: 1 stories28 Jul: 1 stories29 Jul: 1 stories30 Jul: 1 stories31 Jul: 1 stories02 Aug: 1 stories03 Aug: 1 stories04 Aug: 1 stories08 Aug: 1 stories10 Aug: 1 stories13 Aug: 1 stories 17 Jul: tone 57, 1 stories22 Jul: tone 43, 1 stories25 Jul: tone 50, 1 stories28 Jul: tone 50, 1 stories29 Jul: tone 50, 1 stories30 Jul: tone 50, 1 stories31 Jul: tone 75, 1 stories02 Aug: tone 50, 1 stories03 Aug: tone 50, 1 stories04 Aug: tone 50, 1 stories08 Aug: tone 50, 1 stories10 Aug: tone 43, 1 stories13 Aug: tone 63, 1 stories 95505
15 Jul30 Jul13 Aug
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence5
0.243 after freshness weighting
Source breadth100
12 independent publishers
Company relevance100
share tied directly to this company
Freshness54
recency-weighted evidence
Agreement89
how closely stories agree
Publisher mix78
less reliance on one publisher

Price and news history

News score and weekly price over 26 weeks

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb 2026: close 196.52, indexed 100.020 Feb 2026: close 192.03, indexed 97.727 Feb 2026: close 191.82, indexed 97.606 Mar 2026: close 184.87, indexed 94.113 Mar 2026: close 181.55, indexed 92.420 Mar 2026: close 181.46, indexed 92.327 Mar 2026: close 183.84, indexed 93.503 Apr 2026: close 177.34, indexed 90.210 Apr 2026: close 172.97, indexed 88.017 Apr 2026: close 177.35, indexed 90.224 Apr 2026: close 184.38, indexed 93.801 May 2026: close 187.06, indexed 95.208 May 2026: close 193.45, indexed 98.415 May 2026: close 192.95, indexed 98.222 May 2026: close 193.76, indexed 98.629 May 2026: close 196.0, indexed 99.705 Jun 2026: close 195.34, indexed 99.412 Jun 2026: close 200.05, indexed 101.819 Jun 2026: close 196.58, indexed 100.026 Jun 2026: close 216.03, indexed 109.903 Jul 2026: close 216.12, indexed 110.010 Jul 2026: close 199.15, indexed 101.317 Jul 2026: close 205.99, indexed 104.824 Jul 2026: close 202.19, indexed 102.931 Jul 2026: close 202.95, indexed 103.307 Aug 2026: close 207.94, indexed 105.8 19 Jun 2026: news score 49, close 196.58, 3 stories4926 Jun 2026: news score 51, close 216.03, 11 stories03 Jul 2026: news score 50, close 216.12, 18 stories5010 Jul 2026: news score 50, close 199.15, 24 stories17 Jul 2026: news score 51, close 205.99, 25 stories5124 Jul 2026: news score 50, close 202.19, 20 stories31 Jul 2026: news score 54, close 202.95, 18 stories5407 Aug 2026: news score 53, close 207.94, 16 stories53
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
26-week price+5.8%latest close 207.94
News score change+4first to latest comparable week
One-week response+2.5%Price confirming higher
Fair-value position+10.9%Near fair-value range
WeekNews scoreCloseWeekly move
07 Aug 202653USD 207.94+2.5%
31 Jul 202654USD 202.95+0.4%
24 Jul 202650USD 202.19-1.8%
17 Jul 202651USD 205.99+3.4%
10 Jul 202650USD 199.15-7.9%
03 Jul 202650USD 216.12+0.0%
26 Jun 202651USD 216.03+9.9%
19 Jun 202649USD 196.58-1.7%
Provisional evidence

News subjects

What is shaping the score

Earnings
Earnings586 stories · 46%
Market update504 stories · 31%
Analyst action573 stories · 23%

Source mix

Where the evidence comes from

78/100 independence
MarketWatch502 stories · 15%
Simply Wall St751 stories · 8%
finance.yahoo.com631 stories · 8%
www.marketscreener.com431 stories · 8%
Zacks431 stories · 8%
Motley Fool501 stories · 8%
Stock Titan501 stories · 8%

Recurring subjects

Subjects appearing most often

Current evidence
Price Target1Pharma1Earnings Growth1Earnings1Clinical Trials1Balance Sheet1

Earlier readings

How the score has changed

35 comparable readings · 56 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+250 to 52 · Broadly stable
Observed range49–5450 is the neutral baseline
Evidence depth19stories at latest stored reading · +18
Confidence30/100Provisional · +2
18 Jun50 neutral13 Aug 20:36
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
13 Aug 20:3652+030/100 (-1)19 (+1)Provisional
11 Aug 23:5952+031/100 (+1)18 (+2)Provisional
10 Aug 23:5952-130/100 (0)16 (0)Provisional
08 Aug 23:5953+030/100 (0)16 (0)Provisional
07 Aug 23:5953+130/100 (+2)16 (-2)Provisional
04 Aug 23:5952+028/100 (-1)18 (0)Provisional
03 Aug 23:5952-129/100 (0)18 (+1)Provisional
02 Aug 23:5953-129/100 (-3)17 (-1)Provisional

Source headlines

The news behind the score

Showing 1-13 of 13

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#163Tone
finance.yahoo.comDirect company coverageStored article

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations. The firm highlighted litifilimab and felzartamab as key assets, with clinical readouts expected over the coming year. Wolfe said litifilimab could become the first biologic approved for cut

Balance SheetClinical TrialsEarningsEarnings GrowthPharmaPrice Target
Published
13 Aug 2026 13:52
News subject
Analyst action
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
High · 38.3% · 0.3d old
Duplicates
1 consolidated
#243Tone
www.marketscreener.comDirect company coverageScored from headlineSource lookup

HSBC Adjusts Price Target on Biogen to $165 From $157, Keeps Reduce Rating

Published
10 Aug 2026 12:57
News subject
Analyst action
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Medium · 17.5% · 3.3d old
Duplicates
2 consolidated
#350Tone
Motley FoolDirect company coverageScored from headlineSource lookup

Biogen (BIIB) Q2 2026 Earnings Call Transcript

Published
08 Aug 2026 00:02
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Medium · 15.1% · 5.9d old
Duplicates
1 consolidated
#450Tone
Stock TitanDirect company coverageScored from headlineSource lookup

Lloyd Minor (BIIB) files Form 144 for 593-share NASDAQ stock sale

Published
04 Aug 2026 23:57
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1% · 8.9d old
Duplicates
1 consolidated
#550Tone
Investing.com CanadaDirect company coverageScored from headlineSource lookup

Form 144 BIOGEN INC. For: 3 August By Investing.com

Published
03 Aug 2026 23:10
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1% · 9.9d old
Duplicates
1 consolidated
#650Tone
MarketWatchDirect company coverageScored from headlineSource lookup

Biogen Inc. stock underperforms Friday when compared to competitors

Published
02 Aug 2026 10:58
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 0.6% · 11.4d old
Duplicates
1 consolidated
#1050Tone
The Globe and MailDirect company coverageScored from headlineSource lookup

Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings

Published
28 Jul 2026 06:44
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 3.4% · 16.6d old
Duplicates
1 consolidated
#1150Tone
TradingViewDirect company coverageScored from headlineSource lookup

Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?

Published
25 Jul 2026 07:13
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 2.3% · 19.6d old
Duplicates
1 consolidated
#1357Tone
MarketWatchDirect company coverageScored from headlineSource lookup

Biogen Inc. stock outperforms competitors on strong trading day

Published
17 Jul 2026 17:31
News subject
Market update
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 27.1d old
Duplicates
1 consolidated

Earlier company news

BIIB news archive

Showing 1-30 of 30 stored headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Aug 11 2026
finance.yahoo.comArchivedNeutral tone

NovelMed Advances NM5072 for Multiple Ocular Disorders

NovelMed Therapeutics Inc Key Highlights Multi-indication precedent: Biogen's approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan. Primate proof of concept: A single intravitreal dose of NM5072 reduced CNV, hemorrhage, and retinal fibrosis in a rhesus monkey model. Phase I clinical experience: NM5072 completed a Phase I study in 48 healthy volunteers and received FDA Orphan Drug Designation for PNH. Potential extended durability: Rabbit PK/PD data estimated an ocular half-life of seven days. Translational modeling pro

Published
11 Aug 2026 20:27
Catalyst
Deals and strategy
Coverage
Direct company
Duplicates
2 consolidated
Aug 11 2026
finance.yahoo.comArchivedPositive tone

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"

A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo "We are proud to recog

BIOTECHBiotechFDA-APPROVALFda ApprovalPHARMACEUTICALSPharmaceuticals
Published
11 Aug 2026 14:00
Catalyst
Regulatory and legal
Coverage
Direct company
Duplicates
2 consolidated
Aug 07 2026
finance.yahoo.comArchivedPositive tone

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the year-ago quarter. In late March, Denali secured a major regulatory win with the FDA approval of its lead pipeline candidate tividenofusp alfa-eknm, under the brand name Avlayah, for the treatment of Hunter Syndrome (MPS II). The FDA granted accelerated approval to Avlayah, marking the first new treatment option in nearly 20 years for patients with Hunter syndrome, a rare lysosomal storage disorder. I

BIOTECHBiotechCLINICAL-TRIALSClinical TrialsEARNINGSEarnings
Published
7 Aug 2026 19:31
Catalyst
Earnings
Coverage
Direct company
Duplicates
2 consolidated
Jul 03 2026
The Globe and MailArchivedLegacy headline · tone unscoredLegacy source lookup

H.C. Wainwright Remains a Buy on Biogen (BIIB)

Published
3 Jul 2026 19:09
Catalyst
Legacy snapshot
Coverage
Direct company
Duplicates
1 consolidated
Jun 19 2026
Hospital ManagementArchivedLegacy headline · tone unscoredLegacy source lookup

Biogen to acquire RayThera for up to $1bn

Published
19 Jun 2026 13:25
Catalyst
Legacy snapshot
Coverage
Direct company
Duplicates
1 consolidated

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context